Skip to main content

Advertisement

Log in

The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel

  • Clinical Trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Background

Hereditary breast cancer is predominantly associated with germline mutations in the BRCA1 or BRCA2 genes. A few recurring mutations in these genes were reported in ethnically diverse Jewish populations. Since 2013, most oncogenetic laboratories in Israel adopted a two-step approach for BRCA1/2 genotyping, where the first step is genotyping for 14 seemingly recurring mutations—first-pass genotyping. The aim of this study was to assess the yield of this targeted BRCA sequencing.

Methods

Clinical and genotyping data of all individuals who underwent oncogenetic counseling and first-pass BRCA genotyping at the Oncogenetic Service Sheba and Assaf Harofeh Medical Centers from 1 February 2013 to 30 June 2017 were reviewed. All study participants were unrelated to each other.

Results

Overall, 5152 oncogenetic tests were reviewed in the present study, of which 4452 had no a priori known familial mutation. The majority of participants (68.6%) were genotyped because of personal history of cancer; 20.6% were tested because of family history of cancer, and details for the remaining 10.7% were missing. Overall, 256/4452 (5.8%) carriers were detected, 141 BRCA1 and 115 BRCA2 mutation carriers. In 54% of cancer-free carriers, no clinically suspicious family history of cancer was ascertained.

Conclusions

The currently used scheme of first-pass genotyping in Israel seems to have a high yield of mutation detection even in the absence of a significant family history of cancer. The challenge is to optimize the currently used targeted panel of common mutations and adjust it to the accumulating new data in the Israeli population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C et al (1999) Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91:1241–1247

    Article  CAS  PubMed  Google Scholar 

  2. Tobias DH, Eng C, McCurdy LD, Kalir T, Mandelli J, Dottino PR et al (2000) Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients. Gynecol Oncol 78:148–151

    Article  CAS  PubMed  Google Scholar 

  3. Robson M, Dabney MK, Rosenthal G, Ludwig S, Seltzer MH, Gilewski T et al (1997) Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test 1:47–51

    CAS  PubMed  Google Scholar 

  4. Lerer I, Wang T, Peretz T, Sagi M, Kaduri L, Orr-Urtreger A et al (1998) The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. Am J Hum Genet 63:272–274

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Shiri-Sverdlov R, Gershoni-Baruch R, Ichezkel-Hirsch G, Gotlieb WH, Bar-Sade RB, Chetrit A et al (2001) The Tyr978X BRCA1 mutation in non-Ashkenazi Jews: occurrence in high-risk families, general population and unselected ovarian cancer patients. Public Health Genomics 4:50–55

    Article  Google Scholar 

  6. Laitman Y, Simeonov M, Herskovitz L, Kushnir A, Shimon-Paluch S, Kaufman B et al (2012) Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel. Breast Cancer Res Treat 133:1153–1157

    Article  CAS  PubMed  Google Scholar 

  7. Sagi M, Eilat A, Avi LB, Goldberg Y, Bercovich D, Hamburger T et al (2011) Two BRCA1/2 founder mutations in Jews of Sephardic origin. Fam Cancer 10:59–63

    Article  PubMed  Google Scholar 

  8. Laitman Y, Borsthein RT, Stoppa-Lyonnet D, Dagan E, Castera L, Goislard M et al (2011) Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel. Breast Cancer Res Treat 127:489–495

    Article  PubMed  Google Scholar 

  9. Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. The Penn II Risk model, BRCA 1 and BRCA 2 mutation predictor. https://pennmodel2.pmacs.upenn.edu/penn2/index.jsp. Accessed 2 Sep 2017

  11. Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC (2014) BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer 110:535–545

    Article  CAS  PubMed  Google Scholar 

  12. Schayek H, De Marco L, Starinsky-Elbaz S, Rossette M, Laitman Y, Bastos-Rodrigues L et al (2016) The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil. Cancer Genet 209:50–52

    Article  CAS  PubMed  Google Scholar 

  13. Zick A, Cohen S, Hamburger T, Goldberg Y, Zvi N, Sagi M et al (2015) A BRCA1 frame shift mutation in women of Kurdish Jewish descent. Open Med J. https://doi.org/10.2174/1874220301401010031

    Google Scholar 

  14. Zick A, Kadouri L, Cohen S, Frohlinger M, Hamburger T, Zvi N et al (2017) Recurrent TP53 missense mutation in cancer patients of Arab descent. Fam Cancer 16:295–301

    Article  CAS  PubMed  Google Scholar 

  15. Zidan J, Zhou AY, van den Akker J, Laitman Y, Schayek H, Schnaider J et al (2017) Inherited predisposition to breast and ovarian cancer in non-Jewish populations in Israel. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-017-4474-3

    Google Scholar 

  16. Shaag A, Walsh T, Renbaum P, Kirchhoff T, Nafa K, Shiovitz S et al (2005) Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet 14:555–563

    Article  CAS  PubMed  Google Scholar 

  17. Walsh T, Mandell JB, Norquist BM, Casadei S, Gulsuner S, Lee MK et al (2017) Genetic predisposition to breast cancer due to mutations other than BRCA1 and BRCA2 founder alleles among Ashkenazi Jewish women. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2017.1996

    Google Scholar 

  18. Janavičius R (2010) Founder BRCA1/2 mutations in the Europe: implications for hereditary breast–ovarian cancer prevention and control. EPMA J 1:397–412

    Article  PubMed  PubMed Central  Google Scholar 

  19. Weitzel JN, Lagos VI, Cullinane CA, Gambol PJ, Culver JO, Blazer KR et al (2007) Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 297:2587–2595

    Article  CAS  PubMed  Google Scholar 

  20. King M-C, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646

    Article  CAS  PubMed  Google Scholar 

  21. Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64:963–970

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K et al (2015) Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121:25–33

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Eitan Friedman.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bernstein-Molho, R., Laitman, Y., Schayek, H. et al. The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel. Breast Cancer Res Treat 167, 697–702 (2018). https://doi.org/10.1007/s10549-017-4551-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-017-4551-7

Keywords

Navigation